Physician profile
Alexander Mayer
NPI 1023278041
$5,338.53
in general payments reported to CMS, 2019-2025
26 companies · $1,073 in 2025
The $1,073 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,697 · 2020: $657 · 2021: $97.22 · 2022: $654 · 2023: $260 · 2024: $901 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,449.62 | 2019-2025 | Supera, Diamondback Coronary, Dragonfly Opstar |
| Philips North America LLC | $386.05 | 2019-2025 | Ecc Solutions, (Ck4) Mcot, (Ck7) Extended Holter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.11 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $309.67 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $282.71 | 2019-2025 | |
| Heartflow, INC. | $254.81 | 2024-2025 | |
| Shockwave Medical, INC | $227.48 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $216.34 | 2021-2025 | Hawkone, Venaseal |
| Janssen Pharmaceuticals, INC | $180.34 | 2019-2024 | Xarelto |
| Pfizer INC. | $176.01 | 2019-2025 | |
| Terumo Medical Corporation | $173.22 | 2022 | |
| Amgen INC. | $172.51 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $157.07 | 2020-2024 | Varithena Administration Pack |
| Cardiovascular Systems INC. | $151.86 | 2019 | |
| Esperion Therapeutics, INC. | $150.00 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $141.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $116.72 | 2019-2025 | Wainua |
| Merck Sharp & Dohme LLC | $116.61 | 2022-2025 | Verquvo |
| Tactile Systems Technology INC | $83.31 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Bridgebio Pharma, INC. | $77.11 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $72.17 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $38.77 | 2024 | |
| Bard Peripheral Vascular, INC. | $30.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.44 | 2019 | |
| Advanced Oxygen Therapy INC. | $12.40 | 2025 | Topical Oxygen Chamber For Extremities |
| Medtronic Vascular, INC. | $12.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.